Xenetic Biosciences to Host 2017 First Quarter Update Conference Call
May 09 2017 - 8:35AM
Business Wire
- Conference call and live audio webcast on
Tuesday, May 16th at 8:30 AM ET –
Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the
“Company”), a clinical-stage biopharmaceutical company focused on
the discovery, research and development of next-generation biologic
drugs and novel orphan oncology therapeutics, announced today that
it will report its financial results for the quarter ended March
31, 2017 in a press release that will be issued pre-market on
Tuesday, May 16, 2017. Xenetic’s management team also announced
that it will host a quarterly update conference call with a live
audio webcast that same day at 8:30 AM ET to review its operational
progress, expected near-term milestones and financial report.
The conference call and live webcast will be accompanied by a
slide presentation. To participate in the call, please dial (877)
407-6914 (domestic) or (201) 493-6709 (international). The live
webcast and accompanying slides will be available by accessing the
IR Calendar in the Investors section of Xenetic’s website
(www.xeneticbio.com). A replay of the webcast will be available for
90 days, starting approximately two hours after the presentation
ends.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the discovery, research and
development of next-generation biologic drugs and novel orphan
oncology therapeutics. Xenetic's proprietary drug development
platforms include PolyXen™, which enables next generation biologic
drugs by improving their half-life and other pharmacological
properties. Xenetic's lead investigational product candidates
include oncology therapeutic XBIO-101 (sodium cridanimod) for the
treatment of progesterone resistant endometrial cancer (EC), and a
polysialylated form of erythropoietin for the treatment of anemia
in pre-dialysis patients with chronic kidney disease.
Xenetic is also working together with Shire plc
(formerly Baxalta, Baxter Incorporated and Baxter Healthcare)
to develop a novel series of polysialylated blood coagulation
factors, including a next generation Factor VIII. This
collaboration relies on Xenetic's PolyXen technology to conjugate
polysialic acid (“PSA”) to therapeutic blood-clotting factors, with
the goal of improving the pharmacokinetic profile and extending the
active life of these biologic molecules. Shire is a significant
stockholder of the Company, having invested $10 million in the
Company during 2014. The agreement is an exclusive research,
development and license agreement which grants Shire a worldwide,
exclusive, royalty-bearing license to Xenetic's PSA patented and
proprietary technology in combination with Shire's proprietary
molecules designed for the treatment of blood and bleeding
disorders. Under the agreement, Xenetic may receive regulatory and
sales target payments for total potential milestone receipts of up
to $100 million plus royalties on sales. Additionally,
Xenetic has previously received strategic investments from OPKO
Health (Nasdaq: OPK), Serum Institute of India Limited and
Pharmsynthez.
Xenetic is also developing a broad pipeline of clinical
candidates for breakthrough biologics and novel oncology
therapeutics in a number of orphan disease indications. For more
information, please visit the company's website
at www.xeneticbio.com and connect on Twitter, LinkedIn,
Facebook and Google+.
Forward-Looking Statements
This press release contains "forward-looking statements," as
that term is defined under the Private Securities Litigation Reform
Act of 1995 (PSLRA), which statements may be identified by words
such as "expects," "plans," "projects," "will," "may,"
"anticipates," "believes," "should," "intends," "estimates," and
other words of similar meaning, including statements regarding
expected benefits of NGS cancer panels, the ability to accurately
determine the heritable factors increasing the risk of cancer,
permitting tailored treatment, screening and prevention of cancer
in patients, as well as other non-historical statements about our
expectations, beliefs or intentions regarding our business,
technologies and products, financial condition, strategies or
prospects. Many factors could cause our actual activities or
results to differ materially from the activities and results
anticipated in forward-looking statements. These factors include
those described in our filings with the Securities and Exchange
Commission, as well as the risks inherent in funding, developing
and obtaining regulatory approvals of new, commercially-viable and
competitive products and treatments. In addition, forward-looking
statements may also be adversely affected by general market
factors, competitive product development, product availability,
federal and state regulations and legislation, the regulatory
process for new products and indications, manufacturing issues that
may arise, patent positions and litigation, among other factors.
The forward-looking statements contained in this press release
speak only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements. We
intend that all forward-looking statements be subject to the
safe-harbor provisions of the PSLRA.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170509005849/en/
Jenene Thomas Communications, LLC.Jenene Thomas,
908-938-1475jenene@jenenethomascommunications.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2024 to May 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From May 2023 to May 2024